Court Suspends Alnylam Patent-Adjustment Suit Pending Outcome of Separate Litigation | GenomeWeb

By Doug Macron

A US District Court late last month agreed to a request by Alnylam Pharmaceuticals to stay a suit it filed against US Patent and Trademark Office over the terms of a patent submitted by the company’s one-time German subsidiary.

The request, which was submitted jointly with the USPTO, sought to stay the suit until a ruling is made on an appeal in an unrelated but similar patent-term suit that drug makers Wyeth and Elan Pharma filed against the patent office.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.